Shom Goel1; Joyce O’Shaughnessy2; Antoinette R. Tan3; Boris Krastev4; Hope Rugo5; Philippe Aftimos6; Denise A. Yardley7; Zoran Andric8; Curt Wolfgang9; Jessica A. Sorrentino9; Wenli Tao9; Andrew Beelen9; Rajesh Malik9; and Sarika Jain9
This presentation is the intellectual property of the author/presenter. Copies of this poster obtained through QR (Quick Response) and/or text key codes are for personal use only and may not be reproduced without written permission of the authors. Contact them at shom.goel@petermac.org or sjain@g1therapeutics.com for permission to reprint and/or distribute.
1 Peter MacCallum Cancer Centre, Melbourne, Australia; 2 Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA; 3 Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; 4 MHAT Hospital for Women Health Nadezhda, Sofia, Bulgaria; 5 University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA; 6 Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; 7 Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA; 8 Clinical Hospital Centre Bezanijska Kosa, Belgrade, Serbia; 9 G1 Therapeutics, Research Triangle Park, NC, USA
American Society of Clinical Oncology Annual Meeting | June 4–8, 2021 | Chicago, IL, USA
PRESERVE 2 STUDY
STUDY OBJECTIVES
ENDPOINTS
OPTIONAL BIOPSY COLLECTION
STATISTICS
REFERENCES
ACKNOWLEDGMENTS
Study sponsored by G1 Therapeutics. Medical writing assistance was provided by Farhana Burnett, PhD, from Alligent Europe (Envision Pharma Group), funded by G1 Therapeutics.